The averages rose to start the week and Jim Cramer is helping investors navigate the market's moves. First up, fresh off the announcement that Merck will buy Prometheus Biosciences for $11b, Cramer's talking to Merck CEO Rob Davis and Prometheus CEO Mark McKenna to dig deeper into what the deal will mean for investors and patients. Then, the S&P has climbed 8% this year, but is more upside ahead? Cramer's going Off The Charts to find out. Plus, Cramer's exclusive with InMode CEO Moshe Mizrahy.
Mad Money Disclaimer)
